Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-09-01 Epub Date: 2024-06-07 DOI:10.1007/s11912-024-01554-1

Antonio Cigliola, Gagan Prakash, Roger Li, Karima Oualla, Shilpa Gupta, Ashish M Kamat, Jad Chahoud, Andrea Necchi, Philippe E Spiess

{"title":"Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions.","authors":"Antonio Cigliola, Gagan Prakash, Roger Li, Karima Oualla, Shilpa Gupta, Ashish M Kamat, Jad Chahoud, Andrea Necchi, Philippe E Spiess","doi":"10.1007/s11912-024-01554-1","DOIUrl":null,"url":null,"abstract":"Purpose of review: In contemporary urological practice, managing rare genitourinary (GU) malignancies presents significant challenges, necessitating a comprehensive understanding of their unique characteristics and tailored treatment approaches.Recent findings: Rare GU malignancies, whether per se, variants of common histologies, or common tumors in uncommon locations, often lack widely available clinical guidelines. Consequently, treatment decisions are frequently based on empirical evidence, risking suboptimal outcomes. However, recent advances in molecular profiling, targeted therapies, and immunotherapy offer promising avenues for improving management strategies and patient outcomes. This review provides a comprehensive overview of some rare GU malignancies encountered in clinical practice, including their distinct pathological features, current management approaches, and ongoing research directions. Understanding the complexities of these rare tumors and implementing multidisciplinary treatment strategies are essential for optimizing patient care and improving survival outcomes.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"977-990"},"PeriodicalIF":4.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01554-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: In contemporary urological practice, managing rare genitourinary (GU) malignancies presents significant challenges, necessitating a comprehensive understanding of their unique characteristics and tailored treatment approaches.

Recent findings: Rare GU malignancies, whether per se, variants of common histologies, or common tumors in uncommon locations, often lack widely available clinical guidelines. Consequently, treatment decisions are frequently based on empirical evidence, risking suboptimal outcomes. However, recent advances in molecular profiling, targeted therapies, and immunotherapy offer promising avenues for improving management strategies and patient outcomes. This review provides a comprehensive overview of some rare GU malignancies encountered in clinical practice, including their distinct pathological features, current management approaches, and ongoing research directions. Understanding the complexities of these rare tumors and implementing multidisciplinary treatment strategies are essential for optimizing patient care and improving survival outcomes.

Abstract Image

查看原文本刊更多论文

罕见泌尿生殖系统癌症研究的现状和挑战以及未来方向。

综述的目的：在当代泌尿外科临床实践中，罕见泌尿生殖系统（GU）恶性肿瘤的治疗面临着巨大挑战，需要全面了解其独特性和量身定制的治疗方法：最近的研究结果：罕见的泌尿生殖系统恶性肿瘤，无论是其本身、常见组织学的变体，还是不常见部位的常见肿瘤，往往缺乏广泛可用的临床指南。因此，治疗决定往往以经验证据为基础，有可能导致不理想的结果。然而，分子图谱分析、靶向治疗和免疫疗法的最新进展为改善管理策略和患者预后提供了大有希望的途径。本综述全面概述了临床实践中遇到的一些罕见胃泌素瘤恶性肿瘤，包括其独特的病理特征、当前的治疗方法和正在进行的研究方向。了解这些罕见肿瘤的复杂性并实施多学科治疗策略对于优化患者护理和改善生存预后至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.